N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination
N2OFF (NASDAQ: NITO) completed the acquisition of MitoCareX and published a shareholder letter outlining MitoCareX’s strategy, milestones, and pipeline powered by its proprietary MITOLINE™ algorithm.
MitoCareX reports it has identified promising hit compounds with measurable biological activity against a mitochondrial SLC25 transport protein linked to aggressive cancers, and plans hit-to-lead optimization, PK profiling, and nomination of a preclinical development candidate in 2026. Management is pursuing licensing and collaborations to generate non-dilutive revenue and aims to prepare for IND-enabling studies while positioning MITOLINE™ as a scalable discovery engine.
N2OFF (NASDAQ: NITO) ha completato l'acquisizione di MitoCareX e ha pubblicato una lettera agli azionisti che descrive la strategia di MitoCareX, gli obiettivi e il pipeline alimentati dal suo algoritmo proprietario MITOLINE™.
MitoCareX riferisce di aver identificato composti iniziali promettenti con attività biologica misurabile contro una proteina di trasporto mitocondriale SLC25 collegata a tumori aggressivi, e prevede ottimizzazione hit-to-lead, profilo PK e la nomina di un candidato per lo sviluppo preclinico nel 2026. La direzione sta perseguendo licenze e collaborazioni per generare entrate non dilutive e punta a prepararsi per studi abilitanti all'IND, posizionando MITOLINE™ come un motore di scoperta scalabile.
N2OFF (NASDAQ: NITO) ha completado la adquisición de MitoCareX y publicó una carta a los accionistas que describe la estrategia de MitoCareX, los hitos y su pipeline impulsado por su algoritmo propietario MITOLINE™.
MitoCareX informa haber identificado compuestos iniciales prometedores con actividad biológica medible contra una proteína transportadora mitocondrial SLC25 vinculada a cánceres agresivos, y planes de optimización hit-to-lead, perfil PK y nominación de un candidato para desarrollo preclínico en 2026. La dirección busca licencias y colaboraciones para generar ingresos no dilutivos y apunta a prepararse para estudios que habiliten el IND, posicionando MITOLINE™ como un motor de descubrimiento escalable.
N2OFF (NASDAQ: NITO)가 MitoCareX 인수를 완료했고, 주주들에게 보내는 편지를 발표하여 MitoCareX의 전략, 이정표 및 파이프라인이 독점적인 MITOLINE™ 알고리즘으로 구동됨을 설명했습니다.
MitoCareX는 측정 가능한 생물학적 활성을 가진 유망한 타격 화합물을 미토콘드리아 SLC25 운반 단백질과 연관된 공격적 암과 관련하여 식별했다고 보고하며, 2026년 내 히트-투-리드 최적화, PK 프로파일링 및 전임상 개발 후보 물질 지명을 계획합니다. 경영진은 비희석 수익을 창출하기 위한 라이선스 및 협업을 추진하고 IND 가능 연구를 준비하는 한편 MITOLINE™을 확장 가능한 발견 엔진으로 자리매김하려 합니다.
N2OFF (NASDAQ : NITO) a finalisé l'acquisition de MitoCareX et a publié une lettre aux actionnaires décrivant la stratégie de MitoCareX, les jalons et le pipeline propulsé par son algorithme propriétaire MITOLINE™.
MitoCareX indique avoir identifié des composés initiaux prometteurs présentant une activité biologique mesurable contre une protéine de transport mitochondriale SLC25 liée à des cancers agressifs, et prévoit l'optimisation hit-to-lead, le profil PK et la nomination d'un candidat au développement préclinique en 2026. La direction poursuit des licences et des collaborations pour générer des revenus non dilutifs et vise à se préparer à des études IND-Enable tout en positionnant MITOLINE™ comme un moteur de découverte évolutif.
N2OFF (NASDAQ: NITO) hat die Übernahme von MitoCareX abgeschlossen und einen Aktionärsbrief veröffentlicht, der die Strategie von MitoCareX, Meilensteine und die Pipeline beschreibt, die von ihrem eigenen MITOLINE™-Algorithmus angetrieben wird.
MitoCareX berichtet, dass vielversprechende Treffer-Verbindungen mit messbarer biologischer Aktivität gegen ein mitochondriales Transportprotein SLC25 identifiziert wurden, das mit aggressiven Krebsarten in Verbindung steht, und plant Hit-to-Lead-Optimierung, PK-Profiling und die Nominierung eines Kandidaten für die präklinische Entwicklung im Jahr 2026. Die Geschäftsführung verfolgt Lizenzen und Kooperationen, um nicht-verwässernde Einnahmen zu generieren, und beabsichtigt, sich auf IND-ermittelnde Studien vorzubereiten, während MITOLINE™ als skalierbare Entdeckungsmaschine positioniert wird.
N2OFF (NASDAQ: NITO) أكملت استحواذها على MitoCareX ونشرت رسالة إلى المساهمين توضح استراتيجية MitoCareX والمعالم وخط أنابيبها المدفوع بخوارزمية MITOLINE™ المملوكة.
تفيد MitoCareX بأنها حددت مركبات مبتدئة واعدة مع نشاط بيولوجي قابل للقياس ضد بروتين ناقل ميتوكونדרِي SLC25 المرتبط بسرطانات عدوانية، وتخطط لـ تحسينات تدريب-إلى-قيادة، وتسجيل PK، وترشيح مرشح للتطوير قبل السريري في 2026. تسعى الإدارة إلى الحصول على تراخيص وتعاونات لتوليد إيرادات غير مخفضة وت aims إلى التحضير لدراسات تمكين IND مع وضع MITOLINE™ كآلة اكتشاف قابلة للتوسع.
- Acquisition of MitoCareX completed by N2OFF
- Identified hit compounds with measurable biological activity
- Plan to nominate preclinical development candidate in 2026
- MITOLINE™ positioned for licensing and non-dilutive revenue
- No clinical-stage assets; programs remain preclinical
- Commercial revenue from MITOLINE™ not yet realized
Insights
MitoCareX reports platform-driven hit identification and aims to nominate a preclinical candidate in
By combining a proprietary algorithm (MITOLINE™) with structure-based screening, the team reports repeated identification of biologically active hit compounds against a mitochondrial SLC25 transport protein; this describes a classic discovery funnel where computational models feed high-throughput virtual screens and follow-up experimental validation. The mention of ongoing hit-to-lead medicinal chemistry, pharmacokinetic profiling, and the explicit target of nominating a preclinical development candidate in
Key dependencies and risks remain explicit: success requires that computational models reliably predict tractable chemistry, optimization yields suitable ADME/PK profiles, and biological validation translates to meaningful in vitro and in vivo efficacy. The statement that lung and pancreatic cancers together represent a market exceeding
Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, following the completion of its acquisition of MitoCareX Bio Ltd., today shared an update from the Chief Executive Officer of MitoCareX, Dr. Alon Silberman, including a shareholder letter that outlines the company’s strategic direction, near-term milestones, and development plans within the rapidly expanding precision oncology market.
Dear Shareholders,
It is with great enthusiasm that we share with you the progress and vision of MitoCareX Bio Ltd., a pioneering biotechnology company powered by MITOLINE™, MitoCareX’s proprietary algorithm designed to enable reliable 3D modeling of mitochondrial transport proteins. MITOLINE™ drives the company’s drug discovery process from concept to validation, supporting the development of novel therapies for hard-to-treat cancers through a uniquely mitochondrial approach. Beyond powering MitoCareX’s internal oncology programs, MITOLINE™ is designed for broader application and future licensing, creating opportunities for collaboration and value generation across the biopharmaceutical ecosystem.
MitoCareX is advancing a precision oncology pipeline targeting a mitochondrial SLC25 transport protein that plays a central role in the metabolic reprogramming of aggressive cancers such as lung and pancreatic cancer - two of the world’s most lethal malignancies, together projected to represent a global therapeutic market exceeding
At the heart of this innovation is MITOLINE™, a proprietary algorithm that translates our deep biological insight into a compounding data asset, one that not only accelerates our internal programs but can also enable recurring, non-dilutive revenue opportunities through possible external collaborations. Enabled by MITOLINE’s outputs - proper sequence alignments, the generation of reliable 3D comparative models of mitochondrial SLC25 transport proteins forms the foundation for high throughput in silico screening of millions of small molecules to identify and prioritize potential drug candidates. By integrating computational 3D modeling and candidate prediction, structure-based drug design, and experimental validation, MitoCareX has created a unified discovery platform that accelerates the path from biological insight to validated drug candidate.
Short-Term Value Creation:
Over the past year, MitoCareX has achieved meaningful scientific and operational milestones. We have continuously identified promising hit compounds with measurable biological activity, validating the predictive ability of our MITOLINE™-based modeling approach. In 2026, our focus will be on hit-to-lead medicinal chemistry optimization, pharmacokinetic profiling, and further biological validation, with the goal of nominating a preclinical development candidate - a key milestone that we expect will de-risk our platform and position the company for its next stage of growth.
In parallel, we are exploring strategic collaborations and potential licensing agreements to expand MITOLINE™’s applications beyond our core programs. Such partnerships would allow external organizations - pharmaceutical companies, AI-driven drug discovery groups, and academic institutions - to leverage our platform while creating non-dilutive revenue opportunities for MitoCareX through licensing or co-development models.
Long-Term Value & Commercial Potential:
Looking beyond 2026, our long-term strategy aims to focus on preparing for IND-enabling studies, a key inflection point that will transition MitoCareX toward clinical readiness, while in parallel we aim to establish MITOLINE™ as a scalable discovery engine. Through licensing, data partnerships, and co-development programs, MITOLINE™ has the potential to generate recurring revenue streams while extending MitoCareX’s scientific reach into adjacent areas such as metabolic disorders and inflammatory diseases. This platform-based approach should enable a repeatable, asset-light model that supports sustained value creation for shareholders as our portfolio and collaborations grow.
Strategic Position & Outlook:
MitoCareX’s approach sits at the convergence of mitochondrial biology, computational modeling, and precision oncology, three areas now driving significant investor and industry interest in biotech. Our differentiated focus on the mitochondrial SLC25 family - combined with the potential scalability of MITOLINE™ - positions us uniquely within the next generation of drug discovery companies.
We believe that the future of targeted therapeutics lies in the precise understanding and manipulation of cellular metabolism. By focusing on mitochondrial transporters, MitoCareX is pioneering a new therapeutic frontier aimed at transforming outcomes for patients with cancers and possibly other metabolic disorders that currently lack effective treatments.
Our mission extends beyond a single asset, it’s to build a repeatable, data-driven discovery platform that transforms mitochondrial biology into a sustained engine of innovation and value creation.
We are proud of what the MitoCareX team has achieved and deeply grateful for the continued support of our investors, partners, and advisors. As we continue to execute our scientific and strategic milestones, our goal remains clear: to translate breakthrough mitochondrial insights into tangible value for patients and shareholders alike.
About N2OFF, Inc:
N2OFF is a cleantech company mainly engaged in EU based solar assets using the RTB (Ready to Build ) business model. N2OFF is currently the lead investor in four solar projects in three different EU countries, all of which were introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.
N2OFF also controls approximately
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties including operational and business opportunities available to N2OFF following the acquisition of MitoCareX and the potential benefits MitoCareX can present to N2OFF, and risks and uncertainties relating to MitoCareX’s ability to advance its product candidates through hit-to-lead medicinal chemistry optimization, pharmacokinetic profiling, preclinical and clinical development, to achieve planned preclinical and clinical milestones, and to enter into and maintain strategic collaborations or potential licensing arrangements to expand applications of its technologies beyond its core programs. Actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including market conditions as well as those discussed under the heading “Risk Factors” in N2OFF’s Annual Report on Form 10-K filed with the SEC on March 31, 2025, and in any subsequent filings with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.
Investor Relations Contact:
Michal Efraty
michal@efraty.com
FAQ
What did N2OFF announce about MitoCareX on November 18, 2025 (NITO)?
What is MITOLINE™ and how does it support MitoCareX (NITO)?
What near-term scientific milestone did MitoCareX set for 2026 (NITO)?
Has MitoCareX reported any validated compounds (NITO)?
Will MitoCareX pursue partnerships or licensing for MITOLINE™ (NITO)?
What is the clinical status of MitoCareX’s oncology programs (NITO)?
